ArticleAmerican journal of hematology2019
Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.
Article in American journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 3 syntheses or guidelines pooled it, 170 citations in OpenAlex.
- Elevated D-dimer levels in high-risk multiple myeloma patients: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Pooled it
- Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy.Hematology. American Society of Hematology. Education Program · 2022Pooled it
- Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.British journal of haematology · 2022Trial
- Trial
- Verification and optimization of the VTE risk stratification system for multiple myeloma.Journal of thrombosis and thrombolysis · 2026Article
- Pulmonary embolism associated with CRBN-targeting immunomodulatory drugs: a FAERS-based pharmacovigilance and mechanistic analysis.Journal of thrombosis and thrombolysis · 2026Article
- Statin exposure after multiple myeloma diagnosis and risk of all-cause mortality, venous thromboembolism, pathological fractures, and acute kidney injury: a propensity score-matched retrospective cohort study.Annals of medicine and surgery (2012) · 2026Article
- Geriatric nutritional risk index for the prediction of venous thrombotic events in multiple myeloma.International journal of clinical oncology · 2026Article
- Article
- Machine learning survival model for personalised prevention of catheter-related thrombosis in tumour patients.Communications medicine · 2026Article
- Risk factors for venous thromboembolism in newly diagnosed multiple myeloma patients based on thrombosis prophylaxis.Annals of hematology · 2026Article
- Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism.International journal of molecular sciences · 2026Review
- Universal Use of Novel Oral Anticoagulant Prophylaxis in Myeloma Patients Undergoing IMiD-Based Therapy: Real-World Experience.Journal of clinical medicine · 2026Article
- Clinical factors associated with venous thromboembolism in multiple myeloma patients treated with daratumumab.Discover medicine · 2026Article
- Commentary: Rituximab combined with lenalidomide for the treatment of marginal zone lymphoma with IgM kappa positivity and cold agglutinin syndrome: a case report.Frontiers in immunology · 2026Article
- Development and validation of the CHI-CAT score: a novel tool for assessing cancer-associated venous thromboembolism risk in China.BMC cancer · 2025Article
- Anticoagulants in hematologic malignancies: what is the data?Hematology. American Society of Hematology. Education Program · 2025Review
- Thromboembolism and bleeding in newly diagnosed multiple myeloma: rates, risk profile, and patterns of thromboprophylaxis.Research and practice in thrombosis and haemostasis · 2025Article
- Exploring the Emerging Association Between Immune Checkpoint Inhibitors and Thrombosis.Journal of clinical medicine · 2025Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 1 country.
Funding
Abstract
Venous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with multiple myeloma (MM). The International Myeloma Working Group (IMWG) developed guidelines recommending primary thromboprophylaxis, in those identified at high-risk of VTE by the presence of risk factors. The National Comprehensive Cancer Network (NCCN) has adopted these guidelines; however, they lack validation. We sought to develop and validate a risk prediction score for VTE in MM and to evaluate the performance of the current IMWG/NCCN guidelines. Using 4446 patients within the Veterans Administration Central Cancer Registry, we used time-to-event analyses to develop a risk score for VTE in patients with newly diagnosed MM starting chemotherapy. We externally validated the score using the Surveillance, Epidemiology, End Results (SEER)-Medicare database (N = 4256). After identifying independent predictors of VTE, we combined the variables to develop the IMPEDE VTE score (Immunomodulatory agent; Body Mass Index ≥25 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.